Yun Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yun Wang has a total of 216 co-authors. Here are the top co-authors by number of shared publications:
Hanlu Zhang
Department of Thoracic Surgery, West China Hospital, Sichuan University, Sichuan, CHINA
24 shared publicationsFuqiang Wang
Department of Thoracic Surgery, West China Hospital, Sichuan University, Sichuan, CHINA
20 shared publicationsYu Zheng
Sichuan Univ, West China Hosp, Dept Thorac Surg, 37 Guoxue Alley, Chengdu 610041, Sichuan, Peoples R China
13 shared publicationsFu-Qiang Wang
Department of Thoracic Surgery, West China hospital, SiChuan University, Chengdu, China; Institution of thoracic oncology, West China hospital, SiChuan University, Chengdu, China
11 shared publicationsGuanghao Qiu
Center of Gerontology and Geriatrics, Laboratory of Metabolism and Aging Research, State Key Laboratory of Respiratory Health and Multimorbidity, West China Hospital, National Clinical Research Center for Geriatrics, Sichuan University, Chengdu, China
11 shared publicationsLei Peng
Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, China
10 shared publications
Latest Publications
- 20 July 2026
- Published by Springer Nature in Journal of Robotic Surgery
- Vol. 20 (1) , 661
Management of thymic epithelial tumors more than 5 cm with subxiphoid robotic thymectomy: perioperative and mid-term outcomes
To assess feasibility and oncological results of subxiphoid robotic thymectomy by comparing perioperative and survival outcomes between large (≥ 5 cm) and small (< 5 cm) thymic epithelial tumors (TETs). This retrospective research contained 145 patients with TETs undergoing subxiphoid robotic thymectomy between September 2016 and November 2022. Patients were assigned into large and small tumor group according to maximum diameter on chest CT. The large and small tumor groups included 51 and 94 patients respectively. All patients underwent R0 resection. Patients with large tumor group had prolonged surgical time (135 vs. 120 min, p = 0.005). Other characteristics including pathology, length of hospital stay, TNM stage and tumor invasion were not significantly different between groups. Median follow-up was 65 months. 62.8% of patients completed 5 years of follow-up. Five-year FFR (85.2% vs. 93.4%, p = 0.18), OS (92.6% vs. 95.5%, p = 0.75), and DFS (85.2% vs. 89.9%, p = 0.61) were comparable between large and small tumor groups. In contrast, FFR differed significantly by histotype (p = 0.0001). Among patients undergoing subxiphoid robotic thymectomy, there is no significant differences in survival outcomes over 5 years between large and small tumors.
- 20 July 2026
- Published by Springer Nature in Journal of Robotic Surgery
- Vol. 20 (1) , 661
Management of thymic epithelial tumors more than 5 cm with subxiphoid robotic thymectomy: perioperative and mid-term outcomes
To assess feasibility and oncological results of subxiphoid robotic thymectomy by comparing perioperative and survival outcomes between large (≥ 5 cm) and small (< 5 cm) thymic epithelial tumors (TETs). This retrospective research contained 145 patients with TETs undergoing subxiphoid robotic thymectomy between September 2016 and November 2022. Patients were assigned into large and small tumor group according to maximum diameter on chest CT. The large and small tumor groups included 51 and 94 patients respectively. All patients underwent R0 resection. Patients with large tumor group had prolonged surgical time (135 vs. 120 min, p = 0.005). Other characteristics including pathology, length of hospital stay, TNM stage and tumor invasion were not significantly different between groups. Median follow-up was 65 months. 62.8% of patients completed 5 years of follow-up. Five-year FFR (85.2% vs. 93.4%, p = 0.18), OS (92.6% vs. 95.5%, p = 0.75), and DFS (85.2% vs. 89.9%, p = 0.61) were comparable between large and small tumor groups. In contrast, FFR differed significantly by histotype (p = 0.0001). Among patients undergoing subxiphoid robotic thymectomy, there is no significant differences in survival outcomes over 5 years between large and small tumors.
- 7 July 2026
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 172 (4) , 820-831.e6
Oncological Outcomes of Left Upper Tri-segmentectomy vs. Lobectomy for Clinical Stage I NSCLC with Occult Lymph Node Metastasis: A Target Trial Emulation with Targeted Minimum Loss-Based Estimation and Propensity Score Matching
- 7 July 2026
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 172 (4) , 820-831.e6
Oncological Outcomes of Left Upper Tri-segmentectomy vs. Lobectomy for Clinical Stage I NSCLC with Occult Lymph Node Metastasis: A Target Trial Emulation with Targeted Minimum Loss-Based Estimation and Propensity Score Matching
- Open Access
- 1 February 2026
- Published by SAGE Publications in Digital Health
- Vol. 12
Head-to-head evaluation of large language models for automated risk of bias assessment in randomized controlled trials: A two-phase diagnostic study with meta-reanalysis
Objective: Large language models (LLMs) are emerging as promising tools in medical research, yet their feasibility for automating risk-of-bias assessment in systematic reviews and meta-analyses (SR/MAs) remains underexplored. To this end, we systematically evaluated the accuracy, consistency, and efficiency of two representative LLMs in conducting Cochrane Risk of Bias 2 (RoB-2) assessments, through a head-to-head comparison integrated with a two-phase analytical design that introduced post-hoc chain-of-thought prompt optimization to mirror the human adjudication process. A subsequent meta-reanalysis further traced the downstream impact of LLM-flagged high-risk-of-bias judgments on the robustness of pooled evidence. Methods: In a two-phase diagnostic study design, two representative LLMs (LLM-1, open-source; LLM-2, commercial) assessed 56 randomized controlled trials (RCTs) from five systematic reviews and meta-analyses. Standard RoB-2based prompts were refined post hoc through chain-of-thought prompting to mitigate overly risk-averse ratings. LLM assessments were compared against human reference standards from the original reviews. Performance was quantified via confusion matrices, accuracy, F1-score, Matthews Correlation Coefficient (MCC), and Cohen’s kappa. Results: In post-hoc analysis, binary classification accuracy reached 86.8% (LLM-1) and 89.3% (LLM-2); ternary accuracy reached 85.7% and 87.5%, respectively. MCC exceeded 0.6 for both models, and inter-model kappa improved to 0.601, indicating moderate to high consistency. LLMs reduced assessment time by approximately 16 minutes per RCT compared with manual evaluators. Excluding LLM identified high risk RCTs in meta reanalysis strengthened evidence robustness without altering effect directions. Conclusion: LLMs demonstrated high diagnostic accuracy (binary accuracy: 89.3%; ternary accuracy: 87.5%) and reduced assessment time by approximately 16 minutes per RCT compared with manual evaluation. However, both models showed limited ability to reliably distinguish “Some concerns” from “High risk” judgments, and performance depended on post-hoc chain-of-thought prompt optimization. These findings indicate that LLMs are not yet suitable for fully autonomous bias assessment and should be deployed as adjunctive tools, with human oversight retained for final judgments.
- 1 February 2026
- Published by SAGE Publications in Digital Health
- Vol. 12
Open AccessHead-to-head evaluation of large language models for automated risk of bias assessment in randomized controlled trials: A two-phase diagnostic study with meta-reanalysis
Objective: Large language models (LLMs) are emerging as promising tools in medical research, yet their feasibility for automating risk-of-bias assessment in systematic reviews and meta-analyses (SR/MAs) remains underexplored. To this end, we systematically evaluated the accuracy, consistency, and efficiency of two representative LLMs in conducting Cochrane Risk of Bias 2 (RoB-2) assessments, through a head-to-head comparison integrated with a two-phase analytical design that introduced post-hoc chain-of-thought prompt optimization to mirror the human adjudication process. A subsequent meta-reanalysis further traced the downstream impact of LLM-flagged high-risk-of-bias judgments on the robustness of pooled evidence. Methods: In a two-phase diagnostic study design, two representative LLMs (LLM-1, open-source; LLM-2, commercial) assessed 56 randomized controlled trials (RCTs) from five systematic reviews and meta-analyses. Standard RoB-2based prompts were refined post hoc through chain-of-thought prompting to mitigate overly risk-averse ratings. LLM assessments were compared against human reference standards from the original reviews. Performance was quantified via confusion matrices, accuracy, F1-score, Matthews Correlation Coefficient (MCC), and Cohen’s kappa. Results: In post-hoc analysis, binary classification accuracy reached 86.8% (LLM-1) and 89.3% (LLM-2); ternary accuracy reached 85.7% and 87.5%, respectively. MCC exceeded 0.6 for both models, and inter-model kappa improved to 0.601, indicating moderate to high consistency. LLMs reduced assessment time by approximately 16 minutes per RCT compared with manual evaluators. Excluding LLM identified high risk RCTs in meta reanalysis strengthened evidence robustness without altering effect directions. Conclusion: LLMs demonstrated high diagnostic accuracy (binary accuracy: 89.3%; ternary accuracy: 87.5%) and reduced assessment time by approximately 16 minutes per RCT compared with manual evaluation. However, both models showed limited ability to reliably distinguish “Some concerns” from “High risk” judgments, and performance depended on post-hoc chain-of-thought prompt optimization. These findings indicate that LLMs are not yet suitable for fully autonomous bias assessment and should be deployed as adjunctive tools, with human oversight retained for final judgments.
- Open Access
- 1 February 2026
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 18 (2) , 104
Global and Chinese trends in disease burden of interstitial lung disease and pulmonary sarcoidosis from 1990 to 2021 with projections to 2040: a COVID-19 impact analysis based on the Global Burden of Disease Study 2021
Background: Despite the growing recognition of interstitial lung disease (ILD), updated estimates of its global burden that account for the disruptions of the coronavirus disease 2019 (COVID-19) pandemic are currently unavailable. This study updates the global and Chinese ILD burden using Global Burden of Disease (GBD) 2021 data, analyzing trend deviations during the COVID-19 period and examining disparities between high- and low-resource settings. Methods: We used data from the GBD 2021 study to analyze the global and Chinese burden of ILD. Joinpoint regression analyzed temporal trends in age-standardized incidence rate (ASIR), prevalence rate (ASPR), mortality rate (ASMR), and disability-adjusted life years rate (ASDR). Age-period-cohort (APC) analysis and autoregressive integrated moving average projection model was also used. Results: Globally, ILD and sarcoidosis caused 390,267 incident cases and 188,222 deaths in 2021, with males bearing over half the disease burden. From 1990 to 2021, ASIR increased from 3.77 to 4.54, ASPR from 45.99 to 50.01, ASMR from 1.52 to 2.28, and ASDR from 37.15 to 47.62 (all per 100,000 individuals). These age-standardized rates (ASRs) demonstrated distinct temporal patterns, with an initial increase from 1990 to 2019, followed by a decline from 2019 to 2021. In China, specifically, the ASRs exhibited a more complex pattern: an initial decrease, followed by an increase and subsequent decrease, ultimately showing an upward trend over the 1990–2021 period. APC analysis indicated a positive correlation between disease burden and age. Future projections indicate a declining trend across all metrics by 2040, with consistently higher rates observed in males compared to females. Conclusions: Due to the impact of COVID-19, the global and Chinese burden of ILD and sarcoidosis showed a decline during 2019–2021, interrupting its previous upward trend. The disease burden was particularly severe among economically disadvantaged regions, elderly populations and males. While projections indicate a potential stabilization or decline in ASRs through 2040, these trends must be interpreted with caution due to potential confounding effects of pandemic-related diagnostic disruptions. Substantial regional disparities and increasing burdens in specific age groups demand targeted interventions.
- 1 February 2026
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 18 (2) , 104
Open AccessGlobal and Chinese trends in disease burden of interstitial lung disease and pulmonary sarcoidosis from 1990 to 2021 with projections to 2040: a COVID-19 impact analysis based on the Global Burden of Disease Study 2021
Background: Despite the growing recognition of interstitial lung disease (ILD), updated estimates of its global burden that account for the disruptions of the coronavirus disease 2019 (COVID-19) pandemic are currently unavailable. This study updates the global and Chinese ILD burden using Global Burden of Disease (GBD) 2021 data, analyzing trend deviations during the COVID-19 period and examining disparities between high- and low-resource settings. Methods: We used data from the GBD 2021 study to analyze the global and Chinese burden of ILD. Joinpoint regression analyzed temporal trends in age-standardized incidence rate (ASIR), prevalence rate (ASPR), mortality rate (ASMR), and disability-adjusted life years rate (ASDR). Age-period-cohort (APC) analysis and autoregressive integrated moving average projection model was also used. Results: Globally, ILD and sarcoidosis caused 390,267 incident cases and 188,222 deaths in 2021, with males bearing over half the disease burden. From 1990 to 2021, ASIR increased from 3.77 to 4.54, ASPR from 45.99 to 50.01, ASMR from 1.52 to 2.28, and ASDR from 37.15 to 47.62 (all per 100,000 individuals). These age-standardized rates (ASRs) demonstrated distinct temporal patterns, with an initial increase from 1990 to 2019, followed by a decline from 2019 to 2021. In China, specifically, the ASRs exhibited a more complex pattern: an initial decrease, followed by an increase and subsequent decrease, ultimately showing an upward trend over the 1990–2021 period. APC analysis indicated a positive correlation between disease burden and age. Future projections indicate a declining trend across all metrics by 2040, with consistently higher rates observed in males compared to females. Conclusions: Due to the impact of COVID-19, the global and Chinese burden of ILD and sarcoidosis showed a decline during 2019–2021, interrupting its previous upward trend. The disease burden was particularly severe among economically disadvantaged regions, elderly populations and males. While projections indicate a potential stabilization or decline in ASRs through 2040, these trends must be interpreted with caution due to potential confounding effects of pandemic-related diagnostic disruptions. Substantial regional disparities and increasing burdens in specific age groups demand targeted interventions.
- Open Access
- 18 November 2025
- Published by Springer Nature in Cancer Cell International
- Vol. 25 (1) , 412
Unveiling the role of m6A modification in esophageal cancer: a new frontier in tumor innate interferon immunity
Esophageal cancer (ESCA) is one of the most common and aggressive malignancies worldwide and has a poor prognosis in its late stages, posing a significant threat to human health. N6-methyladenosine (m6A) is the most prevalent RNA chemical modification in eukaryotes, which has gained substantial attention for its critical role in regulating RNA stability, splicing, translation, and localization. Although m6A modification has been found implicated in the initiation and progression of various cancers, its specific mechanisms in ESCA remain underexplored. Concurrently, it's well-recognized that innate immunity is the body's first line of defense against pathogens, playing a vital role in tumor immune surveillance. Additionally, m6A modification has been shown to regulate multiple key innate immune signaling pathways, including the cGAS-STING, Toll-like receptor (TLR), and RIG-I-like receptor (RLR) pathways, which are integral to immune responses and closely linked to several diseases. However, the exact role of m6A in modulating these innate immune pathways in ESCA remains largely unclear. Therefore, this review aimed to explore the interplay between m6A modification and innate immune signaling in ESCA. The findings of this article may provide novel insights into the role of m6A in immune evasion and lay a solid foundation for developing novel immunotherapeutic strategies.
- 18 November 2025
- Published by Springer Nature in Cancer Cell International
- Vol. 25 (1) , 412
Open AccessUnveiling the role of m6A modification in esophageal cancer: a new frontier in tumor innate interferon immunity
Esophageal cancer (ESCA) is one of the most common and aggressive malignancies worldwide and has a poor prognosis in its late stages, posing a significant threat to human health. N6-methyladenosine (m6A) is the most prevalent RNA chemical modification in eukaryotes, which has gained substantial attention for its critical role in regulating RNA stability, splicing, translation, and localization. Although m6A modification has been found implicated in the initiation and progression of various cancers, its specific mechanisms in ESCA remain underexplored. Concurrently, it's well-recognized that innate immunity is the body's first line of defense against pathogens, playing a vital role in tumor immune surveillance. Additionally, m6A modification has been shown to regulate multiple key innate immune signaling pathways, including the cGAS-STING, Toll-like receptor (TLR), and RIG-I-like receptor (RLR) pathways, which are integral to immune responses and closely linked to several diseases. However, the exact role of m6A in modulating these innate immune pathways in ESCA remains largely unclear. Therefore, this review aimed to explore the interplay between m6A modification and innate immune signaling in ESCA. The findings of this article may provide novel insights into the role of m6A in immune evasion and lay a solid foundation for developing novel immunotherapeutic strategies.
- 5 September 2025
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 32 (12) , 9296-9297
ASO Visual Abstract: Analysis of Individual Patient Data Demonstrates that Sublobar Resection Followed by Adjuvant Chemotherapy has Equivalent Prognosis to Lobectomy in Stage I Non-Small Cell Lung Cancer Patients with Spread Through Air Spaces
- 5 September 2025
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 32 (12) , 9296-9297
ASO Visual Abstract: Analysis of Individual Patient Data Demonstrates that Sublobar Resection Followed by Adjuvant Chemotherapy has Equivalent Prognosis to Lobectomy in Stage I Non-Small Cell Lung Cancer Patients with Spread Through Air Spaces
- Open Access
- 20 August 2025
- Published by Springer Nature in European Journal of Medical Research
- Vol. 30 (1) , 1-12
The efficacy and safety of efgartigimod for refractory myasthenia gravis: a systematic review and meta-analysis
Myasthenia gravis (MG) is a chronic autoimmune disorder affecting the neuromuscular junction, where autoreactive immunoglobulin G (IgG) plays a key role in disease pathogenesis. The novel biologic Efgartigimod is a neonatal Fc receptor (FcRn) antagonist, promotes the lysosomal degradation of IgG, and may offer a targeted approach for managing MG. Despite the growing interest in efgartigimod, there remains a lack of comprehensive evaluation of its efficacy and safety in different MG subtypes. Comprehensive retrieval and screening were conducted on Pubmed, Embase, Web of Science, and Cochrane library to search studies on efgartigimod treatment. The data on response rates and adverse events were extracted, and the pooled effect size (ES) with the 95% confidence interval (CI) was calculated by fixed or random effect models. Sensitivity analysis and subgroup analysis were employed to test the heterogeneity. Funnel plots and trim-and-fill methods were used to test for publication bias. Data from 10 studies involving 305 patients were analyzed. The overall treatment response rate was 78% (95% CI: 67%–87%, I2 = 73.4%). Subgroup analysis revealed pooled response rates of 79.2% (95% CI: 68.5%–88.4%, I2 = 25.08%) in acetylcholine receptor antibody-positive MG (AChR+MG) patients and 76.2% (95% CI: 56.8%–91.5%, I2 = 85.95%) in group that did not differentiate auto-antibody types. The pooled incidence of adverse events was 38% (95% CI: 17%–51%, I2 = 92.59%), with infections (7%, 95% CI: 2%–14%, I2 = 62.5%), headache (7%, 95% CI: 1%–18%, I2 = 82.69%) and other (16%, 95% CI: 7%–28%, I2 = 71.81%). Among them, grade 3–4 adverse events are 1% (95% CI: 0%–2%, I2 = 0%). Our study demonstrates that efgartigimod is highly effective and well-tolerated in patients with refractory MG. These findings suggest that efgartigimod is a promising drug for the treatment of MG.
- 20 August 2025
- Published by Springer Nature in European Journal of Medical Research
- Vol. 30 (1) , 1-12
Open AccessThe efficacy and safety of efgartigimod for refractory myasthenia gravis: a systematic review and meta-analysis
Myasthenia gravis (MG) is a chronic autoimmune disorder affecting the neuromuscular junction, where autoreactive immunoglobulin G (IgG) plays a key role in disease pathogenesis. The novel biologic Efgartigimod is a neonatal Fc receptor (FcRn) antagonist, promotes the lysosomal degradation of IgG, and may offer a targeted approach for managing MG. Despite the growing interest in efgartigimod, there remains a lack of comprehensive evaluation of its efficacy and safety in different MG subtypes. Comprehensive retrieval and screening were conducted on Pubmed, Embase, Web of Science, and Cochrane library to search studies on efgartigimod treatment. The data on response rates and adverse events were extracted, and the pooled effect size (ES) with the 95% confidence interval (CI) was calculated by fixed or random effect models. Sensitivity analysis and subgroup analysis were employed to test the heterogeneity. Funnel plots and trim-and-fill methods were used to test for publication bias. Data from 10 studies involving 305 patients were analyzed. The overall treatment response rate was 78% (95% CI: 67%–87%, I2 = 73.4%). Subgroup analysis revealed pooled response rates of 79.2% (95% CI: 68.5%–88.4%, I2 = 25.08%) in acetylcholine receptor antibody-positive MG (AChR+MG) patients and 76.2% (95% CI: 56.8%–91.5%, I2 = 85.95%) in group that did not differentiate auto-antibody types. The pooled incidence of adverse events was 38% (95% CI: 17%–51%, I2 = 92.59%), with infections (7%, 95% CI: 2%–14%, I2 = 62.5%), headache (7%, 95% CI: 1%–18%, I2 = 82.69%) and other (16%, 95% CI: 7%–28%, I2 = 71.81%). Among them, grade 3–4 adverse events are 1% (95% CI: 0%–2%, I2 = 0%). Our study demonstrates that efgartigimod is highly effective and well-tolerated in patients with refractory MG. These findings suggest that efgartigimod is a promising drug for the treatment of MG.
- 8 August 2025
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (1) , 453-466
Analysis of Individual Patient Data Demonstrates that Sublobar Resection Followed by Adjuvant Chemotherapy has Equivalent Prognosis to Lobectomy in Patients with Stage I NSCLC with Spread through Air Spaces
Lobectomy (LOB) remains the standard treatment for stage I non-small cell lung cancer (NSCLC), though sublobar resection (SLR) has emerged as a potential alternative with comparable outcomes. Spread through air spaces (STAS) has been confirmed as an independent risk factor after lung cancer surgery. The prognosis differences between LOB and SLR in patients with stage I NSCLC with STAS are controversial. After systematic retrieval across multiple databases, 25 eligible studies involving 14,126 patients were identified. We extracted hazard ratios (HRs) for recurrence-free survival (RFS) and overall survival (OS) comparing lobectomy versus sublobar resection, along with reconstructed individual patient data (IPD) and adjuvant chemotherapy (ACT) records. These datasets were subsequently subjected to meta-analysis with complementary subgroup and sensitivity analyses. STAS was confirmed as an independent risk factor (RFS: HR 2.61, 95% CI 2.17-3.14; OS: HR 2.15, 95% CI 1.75-2.63). In subgroup analysis of SLR versus LOB in patients with STAS, the inferior RFS and comparable OS were observed in the SLR group (RFS: HR 1.70, 95% CI 1.16-2.49, n = 3488; OS: HR 1.10, 95% CI 0.83-1.46, n = 3581). Furthermore, ACT following SLR effectively reduced recurrence risk in STAS-positive patients compared with LOB (LOB: RFS: HR 1.03, 95% CI 0.48-2.22; SLR: RFS: HR 0.44, 95% CI 0.23-0.82). Surgical approach significantly impacts survival outcomes in stage I NSCLC patients with STAS. LOB remains the preferred option due to its lower recurrence rate and prolonged survival outcomes; for high-risk patients undergoing SLR, ACT is recommended in the case of postoperative STAS.
- 8 August 2025
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (1) , 453-466
Analysis of Individual Patient Data Demonstrates that Sublobar Resection Followed by Adjuvant Chemotherapy has Equivalent Prognosis to Lobectomy in Patients with Stage I NSCLC with Spread through Air Spaces
Lobectomy (LOB) remains the standard treatment for stage I non-small cell lung cancer (NSCLC), though sublobar resection (SLR) has emerged as a potential alternative with comparable outcomes. Spread through air spaces (STAS) has been confirmed as an independent risk factor after lung cancer surgery. The prognosis differences between LOB and SLR in patients with stage I NSCLC with STAS are controversial. After systematic retrieval across multiple databases, 25 eligible studies involving 14,126 patients were identified. We extracted hazard ratios (HRs) for recurrence-free survival (RFS) and overall survival (OS) comparing lobectomy versus sublobar resection, along with reconstructed individual patient data (IPD) and adjuvant chemotherapy (ACT) records. These datasets were subsequently subjected to meta-analysis with complementary subgroup and sensitivity analyses. STAS was confirmed as an independent risk factor (RFS: HR 2.61, 95% CI 2.17-3.14; OS: HR 2.15, 95% CI 1.75-2.63). In subgroup analysis of SLR versus LOB in patients with STAS, the inferior RFS and comparable OS were observed in the SLR group (RFS: HR 1.70, 95% CI 1.16-2.49, n = 3488; OS: HR 1.10, 95% CI 0.83-1.46, n = 3581). Furthermore, ACT following SLR effectively reduced recurrence risk in STAS-positive patients compared with LOB (LOB: RFS: HR 1.03, 95% CI 0.48-2.22; SLR: RFS: HR 0.44, 95% CI 0.23-0.82). Surgical approach significantly impacts survival outcomes in stage I NSCLC patients with STAS. LOB remains the preferred option due to its lower recurrence rate and prolonged survival outcomes; for high-risk patients undergoing SLR, ACT is recommended in the case of postoperative STAS.
- 25 March 2025
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 117 (7) , 1474-1484
Dynamic ctDNA informs whole-course postoperative precise management of NSCLC (LUNGCA study)
Background: Circulating tumor DNA (ctDNA) is valuable for detecting minimal residual disease (MRD). However, studies involving long-term blood sampling are required to comprehensively interpret the clinical use of ctDNA analyses. Methods: We conducted a prospective multicenter cohort study (LUNGCA) for dynamic ctDNA monitoring in lung cancer patients receiving curative-intent surgery. ctDNA analysis was conducted on preoperative plasma samples, at postoperative 3 days and 1 month, and then every 3-6 months for up to 3 years. Results: In total, 233 non-small cell lung cancer (NSCLC) patients and 2336 longitudinal plasma samples were included; the median follow-up was 51.4 months. Post-comprehensive treatment (after radical surgery + necessary adjuvant therapy) MRD status was better at predicting relapse than postoperative MRD status (positive predictive value: 100% vs 90.0%; negative predictive value: 90.3% vs 90.1%). Patients with positive pre-adjuvant ctDNA and targetable mutations in tumor tissues had improved recurrence-free survival (RFS) with corresponding adjuvant tyrosine kinase inhibitor (TKI) treatment (hazard ratio [HR] = 0.01, P = .005), but adjuvant chemotherapy failed to improve RFS (HR = 0.6, P = .491). Of patients receiving adjuvant therapies, patients with a negative- or positive-negative ctDNA change pattern had favorable and similar RFS (P = .419), whereas patients with a positive- or negative-positive pattern had worse RFS (P < .001). TKI therapy was more effective than chemotherapy in clearing ctDNA. Post-relapse ctDNA negativity was associated with favorable OS (HR = 0.4; P = .029). Conclusions: Comprehensive interpretation of dynamic ctDNA monitoring data can inform precise whole-course postsurgical management of NSCLC patients.
- 25 March 2025
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 117 (7) , 1474-1484
Dynamic ctDNA informs whole-course postoperative precise management of NSCLC (LUNGCA study)
Background: Circulating tumor DNA (ctDNA) is valuable for detecting minimal residual disease (MRD). However, studies involving long-term blood sampling are required to comprehensively interpret the clinical use of ctDNA analyses. Methods: We conducted a prospective multicenter cohort study (LUNGCA) for dynamic ctDNA monitoring in lung cancer patients receiving curative-intent surgery. ctDNA analysis was conducted on preoperative plasma samples, at postoperative 3 days and 1 month, and then every 3-6 months for up to 3 years. Results: In total, 233 non-small cell lung cancer (NSCLC) patients and 2336 longitudinal plasma samples were included; the median follow-up was 51.4 months. Post-comprehensive treatment (after radical surgery + necessary adjuvant therapy) MRD status was better at predicting relapse than postoperative MRD status (positive predictive value: 100% vs 90.0%; negative predictive value: 90.3% vs 90.1%). Patients with positive pre-adjuvant ctDNA and targetable mutations in tumor tissues had improved recurrence-free survival (RFS) with corresponding adjuvant tyrosine kinase inhibitor (TKI) treatment (hazard ratio [HR] = 0.01, P = .005), but adjuvant chemotherapy failed to improve RFS (HR = 0.6, P = .491). Of patients receiving adjuvant therapies, patients with a negative- or positive-negative ctDNA change pattern had favorable and similar RFS (P = .419), whereas patients with a positive- or negative-positive pattern had worse RFS (P < .001). TKI therapy was more effective than chemotherapy in clearing ctDNA. Post-relapse ctDNA negativity was associated with favorable OS (HR = 0.4; P = .029). Conclusions: Comprehensive interpretation of dynamic ctDNA monitoring data can inform precise whole-course postsurgical management of NSCLC patients.